Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
June 7th, 2018
9.8K views
Here we describe a method to separate and enrich components of the tumor immune and non-immune microenvironment in established subcutaneous tumors. This technique allows for the separate analysis of tumor immune infiltrate and non-immune tumor fractions which can permit comprehensive characterization of the tumor immune microenvironment.
Overview
This article presents a method for separating and enriching components of the tumor immune and non-immune microenvironment in established subcutaneous tumors. The technique enables the analysis of tumor immune infiltrate and non-immune tumor fractions, facilitating a comprehensive characterization of the tumor immune microenvironment.
Key Study Components
Area of Science
- Oncology
- Immunology
- Cell Biology
Background
- Understanding the tumor immune microenvironment is crucial for cancer treatment.
- Profiling immune and non-immune components can reveal treatment-induced changes.
- Current methods may not effectively separate these components.
- This study introduces a novel technique for better analysis.
Purpose of Study
- To provide a method for simultaneous profiling of immune and cancer cell fractions.
- To identify changes in the tumor microenvironment following treatment.
- To enhance the understanding of tumor immunologic states.
Methods Used
- Spraying the mouse with 70% ethanol to prevent contamination.
- Surgically removing subcutaneous tumors while avoiding contaminating tissue.
- Placing tumors in RPMI 1640 medium on ice for analysis.
- Utilizing a 24-well plate for individual tumor processing.
Main Results
- The technique effectively enriches tumor immune and non-immune components.
- Allows for thorough profiling of the tumor immunologic state.
- Facilitates the identification of treatment-induced changes.
- Provides insights into the dynamics of the tumor microenvironment.
Conclusions
- This method is a significant advancement in tumor microenvironment analysis.
- It can help answer key questions in immune oncology.
- Future studies can build on this technique for deeper insights.
Frequently Asked Questions
What is the main goal of this technique?
The main goal is to profile both immune and cancer cell fractions in the tumor microenvironment.
How does this method improve upon existing techniques?
It allows for effective enrichment and separate analysis of immune and non-immune components.
What are the implications of this research?
It can enhance understanding of tumor dynamics and treatment responses in oncology.
What type of tumors were studied?
Established subcutaneous tumors were used for this analysis.
What medium is used for tumor processing?
RPMI 1640 medium without fetal bovine serum is used.
What precautions are taken during tumor removal?
Care is taken to ensure tumors are free of any contaminating tissue.
Executive Industry Relevance
Accurate characterization of the tumor immune microenvironment is essential for evaluating immunotherapeutic efficacy in preclinical models. This method enables separation and enrichment of immune and non-immune tumor fractions, supporting reproducible profiling of treatment-induced changes. It addresses a key discovery-stage challenge by improving immune cell yield and viability for downstream flow cytometry analysis.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by isolating tumor-infiltrating leukocytes for phenotypic and functional analysis.
- Operational Value: Increases yield of CD45+ immune cells more than two-fold compared to standard digestion, improving detection of rare subsets.
- Predictive Confidence: Supports target validation by preserving cellular viability and enabling assessment of immunosuppressive markers in the tumor fraction.
Screening & Assay Development
- Scientific Value: Generates viable single-cell suspensions suitable for multiplex antibody staining and flow cytometric quantification of immune subsets.
- Operational Value: Standardizes tumor dissociation and density-based separation, reducing variability across samples and operators.
- Assay Readiness: Prepares enriched immune and tumor fractions for consistent immunophenotyping and functional assays in drug screening workflows.
Translational & Preclinical Research
- Translational Continuity: Enables spatial profiling of immune heterogeneity by allowing separate digestion of tumor quadrants, supporting biomarker correlation studies.
- Preclinical Model Relevance: Facilitates evaluation of novel immunotherapies by quantifying treatment-induced shifts in myeloid and lymphocyte populations.
- Mechanistic De-risking: Allows parallel analysis of tumor cell viability, apoptosis, proliferation, and immunosuppressive marker expression alongside immune profiling.
Pipeline & Workflow Integration
The method fits within the discovery biology workflow, enabling immune profiling prior to lead identification and preclinical validation stages by providing standardized, viable tumor-derived cell fractions.
- Discovery Biology: Supports hypothesis testing and pathway clarification by isolating immune and tumor compartments for independent analysis.
- Screening: Delivers reproducible, quantitative immune cell readouts that enable comparison across treatment conditions in immuno-oncology screens.
- Analytics: Generates flow cytometry-compatible single-cell suspensions with high viability (70–90%) and enhanced immune cell enrichment for detailed phenotypic analysis.
- Translational Research: Connects discovery findings to preclinical continuity by enabling longitudinal immune monitoring within individual tumors.
- Enterprise Reuse: Establishes a standardized dissociation and separation protocol applicable across multiple subcutaneous tumor models and therapeutic interventions.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in target validation by reducing mechanistic ambiguity in immune-tumor interactions.
- Operational Value: Enhances reproducibility and scalability of tumor processing through defined enzymatic dissociation and density gradient separation steps.
- Strategic Value: Supports better go/no-go decisions by providing quantifiable immune and tumor cell responses to experimental therapies.
- Portfolio Impact: Enables risk-adjusted prioritization of immunotherapeutic candidates based on deep immune microenvironment profiling.
Implementation Considerations
- Requires expertise in aseptic tumor harvest, enzymatic digestion, and density gradient centrifugation techniques.
- Dependent on access to orbital shakers, centrifuges, strainers, and flow cytometry instrumentation for downstream analysis.
- Necessitates standardization across teams to ensure consistent tumor dissociation timing, strainer clearing, and gradient layering to prevent sample mixing.
- Adaptation considerations include optimizing enzyme concentration and incubation time for different tumor types while maintaining cell viability.
- Practical limitations include the need for careful mechanical disaggregation to avoid clogging strainers and the importance of processing samples promptly to preserve viability.
Biopharma FAQs
Why is density gradient centrifugation used in tumor processing?
Density gradient centrifugation separates immune infiltrates from tumor cells based on buoyant density, enabling enriched recovery of CD45+ leukocytes. This step increases immune cell yield more than two-fold compared to digestion alone, improving detection of rare subsets. It preserves cellular viability, supporting downstream functional and phenotypic analysis by flow cytometry.
How does enzymatic dissociation contribute to immune cell recovery?
Enzymatic digestion using collagenase-1, collagenase-4, and DNase I breaks down extracellular matrix to release intact immune and tumor cells from solid tumors. This step is performed at 37°C with orbital shaking to ensure tissue dissociation while preserving epitope integrity. The resulting single-cell suspension is suitable for staining and flow cytometric analysis of immune subsets.
What quantitative measurements enable immune profiling after separation?
Flow cytometry quantifies immune cell abundance and phenotype using surface and intracellular antibody panels targeting CD45 and lineage markers. Viability is assessed via fixable viability dyes, with 70–90% viability reported post-digestion. These measurements allow comparison of immune subset frequencies across tumor regions and treatment conditions.
Why are replication requirements important for immune microenvironment studies?
Replication across tumor quadrants accounts for spatial heterogeneity in immune infiltration, ensuring representative sampling of the entire tumor. Dividing tumors into equal regions with matched dermal and peritoneal exposure reduces bias in immune subset distribution. This approach supports reliable inter-animal and inter-treatment comparisons in preclinical studies.
What statistical analysis is recommended before implementing this method in screening workflows?
Power analysis should be conducted to determine sample size needed to detect biologically relevant changes in immune subset frequencies. Normality testing and variance equivalence checks inform selection of parametric or non-parametric tests for group comparisons. Establishing baseline variability in control tumors is essential for assessing treatment-induced effects with confidence.
